US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

First Trust NYSE Arca Biotechnology Index Fund

268.15

-3.0800-1.14%

Post-market: 268.150.00000.00%19:30 EDT

Volume:23.51K

Turnover:6.32M

Market Cap:2.91B

PE:31.38

High:271.63

Open:271.63

Low:267.73

Close:271.23

52wk High:274.99

52wk Low:173.98

Shares:10.85M

Float Shares:10.85M

Volume Ratio:0.78

T/O Rate:0.22%

Dividend:- -

Dividend Rate:- -

EPS(TTM):8.55

EPS(LYR):37.75

ROE:19.96%

ROA:-0.16%

PB:1.04

PE(LYR):7.10

Loading ...

Overview Company News Filings

Corcept Therapeutics (CORT) Stock Soars 22% After Hours: Here's What You Need To Know

Benzinga Earnings

NeoGenomics (NEO) Stock Rallies As Profit Returns And Margins Improve

Simply Wall St.

Corcept Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Corcept Therapeutics Q2 EPS USD 0.36

Corcept Q2 FY26 Net Income Rises to $43 Million; Revenue Climbs 32% to $256.1 Million

Corcept Therapeutics Q2 Revenue Estimates, Raises 2026 Outlook

Update: NeoGenomics Shares Rise After Q2 Beat

MT Newswires Live

Alkermes' Core Business Backed Q2 Beat, Orexin Pipeline to Serve as Catalyst, RBC Says

MT Newswires Live

Neogenomics Inc : Needham Raises Target Price to $19 from $15

THOMSON REUTERS

Corcept Therapeutics Inc : Canaccord Genuity Raises Target Price to $150 from $135

THOMSON REUTERS

Alkermes Plc : Jefferies Raises Target Price to $72 from $65

THOMSON REUTERS

Alkermes Plc : TD Cowen Raises Target Price to $58 from $57

THOMSON REUTERS

Alkermes Plc : Baird Raises Target Price to $58 from $48

THOMSON REUTERS

Neogenomics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Veracyte to Present at Canaccord Genuity Growth Conference Fireside Chat

Neogenomics Shares Rise 6.5% in Extended Trading After Posting Quarterly Results

THOMSON REUTERS

NeoGenomics Q2 FY26 Adjusted Ebitda Climbs 36% to $14 Million; Revenue Rises 11% to $202 Million

NeoGenomics Q2 Revenue USD 202 Million Vs. IBES Estimate USD 197 Million

Neogenomics Inc: Decrease in Operating Expenses for Q2 2026 was Primarily Due to $20 Mln of Impairment Charges Taken in Q2 2025

THOMSON REUTERS

Neogenomics Q2 Operating Expenses USD 102 Million

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/FBT/news?page=8"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"FBT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FBT\",,,,,undefined,":{"symbol":"FBT","market":"US","secType":"STK","nameCN":"First Trust NYSE Arca Biotechnology Index Fund","latestPrice":268.15,"timestamp":1789761600000,"preClose":271.23,"halted":0,"volume":23507,"hourTrading":{"tag":"盘后","latestPrice":268.15,"preClose":268.15,"latestTime":"19:30 EDT","volume":17,"amount":4553.29,"timestamp":1789774206683,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.011355675994543526,"floatShares":10850002,"shares":10850002,"eps":8.545272,"marketStatus":"Market Closed","change":-3.08,"latestTime":"09-18 16:00:00 EDT","open":271.63,"high":271.63,"low":267.73,"amount":6319864.942380001,"amplitude":0.014379,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":8.545272,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789977600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":271.23,"sharesOutstanding":11450002,"nav":270.95,"aum":2953355541.9,"bidAskSpread":0.00095,"preHourTrading":{"tag":"盘前","latestPrice":271.23,"preClose":271.23,"latestTime":"07:36 EDT","volume":4,"amount":1084.9316,"timestamp":1789731363239,"change":0,"changeRate":0,"amplitude":0.000043},"postHourTrading":{"tag":"盘后","latestPrice":268.15,"preClose":268.15,"latestTime":"19:30 EDT","volume":17,"amount":4553.29,"timestamp":1789774206683,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7794563330839,"impliedVol":0.2045,"impliedVolPercentile":0.4223},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FBT\",,,,,undefined,":{"symbol":"FBT","floatShares":10850002,"roa":"-0.16%","roe":"19.96%","lyrEps":37.754725,"volumeRatio":0.7794563330839,"shares":10850002,"dividePrice":0,"high":271.63,"amplitude":0.014379,"preClose":271.23,"low":267.73,"week52Low":173.975,"pbRate":"1.04","psRate":"701.87","week52High":274.99,"institutionHeld":0,"latestPrice":268.15,"eps":8.545272,"divideRate":0,"volume":23507,"delay":0,"ttmEps":8.545272,"open":271.63,"prevYearClose":206.52,"prevWeekClose":261.85,"prevMonthClose":267.15,"prevQuarterClose":247.89,"fiveDayClose":261.85,"twentyDayClose":268.125,"sixtyDayClose":237.29},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FBT\",params:#limit:5,,,undefined,":[{"date":"2024-12-13","symbol":"FBT","amount":1.1726,"announcedDate":"2024-12-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-13","defaultRemindTime":1734100200000,"name":"First Trust NYSE Arca Biotechnology Index Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-31","payableDate":"2024-12-13","currency":"USD","dateTimestamp":1734066000000,"payDate":"2024-12-31"},{"market":"US","date":"2022-01-10","symbol":"FBT","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1641790800000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2021-12-30","symbol":"FBT","amount":2.2136,"defaultRemindTime":1640874600000,"name":"First Trust NYSE Arca Biotechnology Index Fund","recordDate":"2022-01-10","payableDate":"2021-12-31","currency":"USD","type":"dividend","dateTimestamp":1640840400000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FBT\",market:\"US\",,,undefined,":[{"executeDate":"2021-12-30","recordDate":"2021-12-31","paymentDate":"2022-01-10","value":2.2136,"currency":"USD"},{"executeDate":"2024-12-13","recordDate":"2024-12-13","paymentDate":"2024-12-31","value":1.1726,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FBT\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FBT\",pageSize:20,pageCount:8,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2655782580","title":"Corcept Therapeutics (CORT) Stock Soars 22% After Hours: Here's What You Need To Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2655782580","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655782580?lang=en_us&edition=fundamental","pubTime":"2026-07-30 14:48","pubTimestamp":1785394133,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics shares soared 21.95% after hours as strong quarterly results and raised guidance boosted investor confidence.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/26/07/60787510/corcept-therapeutics-shares-surge-after-hours-q2-results-raised-guidance","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","ODDS","BK4007","CORT","NUWE","PSCH","RSI","BK4532","BK4150","LU1559883803.SGD","BETZ","ODDZ","LU0566484027.USD","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655486328","title":"NeoGenomics (NEO) Stock Rallies As Profit Returns And Margins Improve","url":"https://stock-news.laohu8.com/highlight/detail?id=2655486328","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655486328?lang=en_us&edition=fundamental","pubTime":"2026-07-30 07:23","pubTimestamp":1785367402,"startTime":"0","endTime":"0","summary":"NeoGenomics came into this print as an expensive growth story in cancer diagnostics, with a rich P/S multiple and a long stretch of losses. The stock jumped about 14% to US$15.27 today, which indicates investors liked what they saw. The key focus is margin and profit repair. NeoGenomics moved from a loss in Q1 to a modest profit in Q2 and lifted adjusted EBITDA, helped by higher average price per test and its Lab of the Future efficiency work. The rest of the earnings detail supports that...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-neo/neogenomics/news/neogenomics-neo-stock-rallies-as-profit-returns-and-margins","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-neo/neogenomics/news/neogenomics-neo-stock-rallies-as-profit-returns-and-margins","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0012050646.USD","BK4121","LU0106261612.USD","NEO","BK4196","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655103338","title":"Corcept Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2655103338","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655103338?lang=en_us&edition=fundamental","pubTime":"2026-07-30 06:40","pubTimestamp":1785364847,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryCorcept Therapeutics IncCORT.OQreported quarterly adjusted earnings of 36 cents per share for the quarter ended","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nL8N43V3R6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","FBT","PSCH","CORT","LU1559883803.SGD","BK4007","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655816067","title":"Corcept Therapeutics Q2 EPS USD 0.36","url":"https://stock-news.laohu8.com/highlight/detail?id=2655816067","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655816067?lang=en_us&edition=fundamental","pubTime":"2026-07-30 04:16","pubTimestamp":1785356177,"startTime":"0","endTime":"0","summary":"Jul 29 (Reuters) - Corcept Therapeutics Q2 revenue USD 256.147 million.:((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))Source Date/Time = 29-JUL-202615:42:50 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nRSD73tzLC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0566484027.USD","LU1559883803.SGD","BK4532","BK4007","PSCH","FBT","CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655581677","title":"Corcept Q2 FY26 Net Income Rises to $43 Million; Revenue Climbs 32% to $256.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2655581677","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655581677?lang=en_us&edition=fundamental","pubTime":"2026-07-30 04:15","pubTimestamp":1785356143,"startTime":"0","endTime":"0","summary":"Corcept Q2 FY26 net income rises to $43 million; revenue climbs 32% to $256.1 millionCorcept Q2 revenue rose 32% to USD 256.1 million, with Korlym and authorized generic at USD 208.6 million and Lifyo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nNDL3dG2zq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CORT","BK4532","LU1559883803.SGD","PSCH","LU0566484027.USD","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655162788","title":"Corcept Therapeutics Q2 Revenue Estimates, Raises 2026 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2655162788","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655162788?lang=en_us&edition=fundamental","pubTime":"2026-07-30 04:13","pubTimestamp":1785355980,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics Q2 revenue estimates, raises 2026 outlookOverviewU.S. biopharma firm's Q2 revenue rose 32% yr/yr, beating analyst expectationsNet income for Q2 increased to $43.0 mln from $35.1 m","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nL1N43V1C6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IDNA","BK4533","BK4588","LU0320765992.SGD","BMED","BIIB","BK4532","LU0566484027.USD","LU0234570918.USD","LU1559883803.SGD","FBT","IE00B894F039.SGD","CORT","IE00B19Z9P08.USD","BK4007","LU0109394709.USD","INCY","LU0889565916.HKD","BK4585","BK4550","PSCH","IE00B19Z9Z06.USD","PBE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655981330","title":"Update: NeoGenomics Shares Rise After Q2 Beat","url":"https://stock-news.laohu8.com/highlight/detail?id=2655981330","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655981330?lang=en_us&edition=fundamental","pubTime":"2026-07-30 02:50","pubTimestamp":1785351016,"startTime":"0","endTime":"0","summary":"NeoGenomics  shares were up over 15% in Wednesday trading following its better-than-expected Q2 results.Late Tuesday, the company reported Q2 adjusted earnings of $0.05 per diluted share, up from $0.03 a year earlier.Analysts polled by FactSet expected $0.03.Revenue for the quarter ended June 30 was $201.7 million, up from 181.3 million a year earlier.Analysts expected $196.9 million.The company said it now expects 2026 revenue of $802 million to $806 million, up from its prior range of $797 million to $803 million. Analysts expect $800.4 million.Price: 15.51, Change: +2.11, Percent Change: +15.75","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4196","LU0012050646.USD","NEO","FBT","LU0106261612.USD","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655926538","title":"Alkermes' Core Business Backed Q2 Beat, Orexin Pipeline to Serve as Catalyst, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2655926538","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655926538?lang=en_us&edition=fundamental","pubTime":"2026-07-29 23:53","pubTimestamp":1785340439,"startTime":"0","endTime":"0","summary":"Alkermes'  base business supported the company's Q2 beat, while its orexin pipeline serves as a potential catalyst for future revenue growth, RBC Capital Markets said in a Tuesday note.The company reported a breakeven in Q2, compared with earnings of $0.52 per share a year earlier, and revenue of $496 million, up from $390.7 million. For 2026, Alkermes reiterated its total revenue guidance of $1.73 billion to $1.84 billion.Alkermes' core business drove the quarter's revenue beat, with recent highlights like less generic threat for Vivitrol and expanded access for Lybalvi, RBC said. The quarter also said one-time benefits from patient mix favorability, Lumryz inventory and Consta manufacturing, the brokerage added.Looking forward, investor focus is shifting to the company's orexin pipeline expansion into other indications, which could help pave the way for Alkermes's revenue to exceed $5 billion, RBC noted.RBC has an outperform rating and $56 price target on Alkermes.Price: 48.40, Chang","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ALKS","PSIL","FBT","PSCH","IBRN","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655649208","title":"Neogenomics Inc : Needham Raises Target Price to $19 from $15","url":"https://stock-news.laohu8.com/highlight/detail?id=2655649208","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655649208?lang=en_us&edition=fundamental","pubTime":"2026-07-29 19:07","pubTimestamp":1785323273,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nFWN43V1F4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NEO","BK4121","LU0106261612.USD","FBT","BK4196","LU0012050646.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655856718","title":"Corcept Therapeutics Inc : Canaccord Genuity Raises Target Price to $150 from $135","url":"https://stock-news.laohu8.com/highlight/detail?id=2655856718","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655856718?lang=en_us&edition=fundamental","pubTime":"2026-07-29 13:51","pubTimestamp":1785304262,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nFWN43V0PR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4532","FBT","CORT","BK4007","PSCH","LU0566484027.USD","LU1559883803.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655385647","title":"Alkermes Plc : Jefferies Raises Target Price to $72 from $65","url":"https://stock-news.laohu8.com/highlight/detail?id=2655385647","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655385647?lang=en_us&edition=fundamental","pubTime":"2026-07-29 13:45","pubTimestamp":1785303957,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nFWN43V0L1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBRN","PSCH","BK4139","ALKS","PSIL","FBT","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655855711","title":"Alkermes Plc : TD Cowen Raises Target Price to $58 from $57","url":"https://stock-news.laohu8.com/highlight/detail?id=2655855711","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655855711?lang=en_us&edition=fundamental","pubTime":"2026-07-29 13:22","pubTimestamp":1785302541,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nFWN43V0HB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALKS","PSIL","IBRN","MEDX","FBT","BK4139","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655853939","title":"Alkermes Plc : Baird Raises Target Price to $58 from $48","url":"https://stock-news.laohu8.com/highlight/detail?id=2655853939","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655853939?lang=en_us&edition=fundamental","pubTime":"2026-07-29 12:22","pubTimestamp":1785298959,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nFWN43V062:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBRN","MEDX","PSCH","FBT","BK4139","ALKS","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655839082","title":"Neogenomics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2655839082","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655839082?lang=en_us&edition=fundamental","pubTime":"2026-07-29 08:07","pubTimestamp":1785283662,"startTime":"0","endTime":"0","summary":"Neogenomics Inc reports results for the quarter ended June 30 - Earnings SummaryNeogenomics IncNEO.OQreported quarterly adjusted earnings of 5 cents per share for the quarter ended June 30, higher tha","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nL8N43V00B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","LU0012050646.USD","BK4196","LU0106261612.USD","FBT","NEO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655880040","title":"Veracyte to Present at Canaccord Genuity Growth Conference Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2655880040","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655880040?lang=en_us&edition=fundamental","pubTime":"2026-07-29 04:27","pubTimestamp":1785270434,"startTime":"0","endTime":"0","summary":"Veracyte to present at Canaccord Genuity Growth Conference fireside chatVeracyte will attend the Canaccord Genuity 46th Annual Growth Conference in Boston on Aug. 11, featuring a 10:30 a.m. ET firesid","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nNDL9zWctP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1074936037.SGD","VCYT","LU0106261372.USD","LU0320765646.SGD","LU1548497426.USD","IE00BZ1G4Q59.USD","LU0795875169.SGD","LU0528227936.USD","LU2023251221.USD","LU0106831901.USD","FBT","LU1064131342.USD","LU1791710582.SGD","LU0795875086.SGD","LU1720051017.SGD","LU2357305700.SGD","LU1989772840.SGD","LU2089283258.USD","BK4516","LU0971096721.USD","LU1244550221.USD","BK4127","LU1363072403.SGD","LU1668664300.SGD","BK4504","LU1720051108.HKD","BK4588","LU0267386448.USD","LU0053666078.USD","KBWB","LU0225283273.USD","LU0912757837.SGD","LU0390134368.USD","LU1162221912.USD","LU2111349929.HKD","LU0882574139.USD","LU2133065610.SGD","BK4585","IAI","LU1989772923.USD","LU2089284900.SGD","LU2347655156.SGD","BK4534","LU0210528500.USD","LU2271345857.HKD","LU1791710400.SGD","LU1988902786.USD","LU0006306889.USD","BK4581","LU1244550577.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655288055","title":"Neogenomics Shares Rise 6.5% in Extended Trading After Posting Quarterly Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2655288055","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655288055?lang=en_us&edition=fundamental","pubTime":"2026-07-29 04:15","pubTimestamp":1785269721,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nL6N43U19X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0012050646.USD","NEO","LU0106261612.USD","FBT","BK4121","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655288705","title":"NeoGenomics Q2 FY26 Adjusted Ebitda Climbs 36% to $14 Million; Revenue Rises 11% to $202 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2655288705","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655288705?lang=en_us&edition=fundamental","pubTime":"2026-07-29 04:09","pubTimestamp":1785269346,"startTime":"0","endTime":"0","summary":"NeoGenomics Q2 FY26 adjusted EBITDA climbs 36% to $14 million; revenue rises 11% to $202 millionNeoGenomics posted Q2 2026 revenue of $202 million, up 11% year over year.Adjusted EBITDA climbed 36% to","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nNDL42J9VD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","BK4121","FBT","LU0012050646.USD","LU0106261612.USD","NEO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655780887","title":"NeoGenomics Q2 Revenue USD 202 Million Vs. IBES Estimate USD 197 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2655780887","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655780887?lang=en_us&edition=fundamental","pubTime":"2026-07-29 04:06","pubTimestamp":1785269161,"startTime":"0","endTime":"0","summary":"BRIEF-NeoGenomics Q2 Revenue USD 202 Million Vs. IBES Estimate USD 197 MillionJul 28 (Reuters) - NeoGenomics Q2 adjusted EBITDA USD 14 million.Q2 operating expenses USD 102 millionQ2 adjusted net income USD 7 millionQ2 gross profit USD 92 millionQ2 net income USD 2 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nPLX2GZQJX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","LU0012050646.USD","NEO","FBT","LU0106261612.USD","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655988083","title":"Neogenomics Inc: Decrease in Operating Expenses for Q2 2026 was Primarily Due to $20 Mln of Impairment Charges Taken in Q2 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2655988083","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655988083?lang=en_us&edition=fundamental","pubTime":"2026-07-29 04:05","pubTimestamp":1785269101,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nPLX2GZQJX:12","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4196","LU0106261612.USD","FBT","LU0012050646.USD","NEO","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655872548","title":"Neogenomics Q2 Operating Expenses USD 102 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2655872548","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655872548?lang=en_us&edition=fundamental","pubTime":"2026-07-29 04:05","pubTimestamp":1785269101,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nPLX2GZQJX:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4196","LU0012050646.USD","LU0106261612.USD","FBT","BK4121","NEO"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":8,"totalSize":200,"code":"91000000","status":"200"}]}}